Ann Arbor’s Celsee Inc., a company focused on single-cell analysis, was issued a patent titled “Cell Capture System and Method of Use,” which covers the automation of single-cell partitioning. The company now has 30 issued or allowed patents and applications in its portfolio.
“A strong IP position is essential for ensuring the long-term growth potential for any life sciences company,” says John Stark, CEO of Celsee. “Celsee’s success in obtaining patents reflects the hard work of our … team, and this will support our ongoing commitment to transforming what’s possible in single-cell analysis.”
Celsee’s technology enables high-throughput analysis of single cells with industry-leading capture rates. It uses a gravity-based method to capture and isolate thousands of individual cells while maintaining viability and structural integrity for analysis.
The company’s Genesis System includes on-system reverse transcription and achieves capture efficiencies of more than 70 percent with improved sensitivity compared to other methods for single-cell analysis.
Celsee has been issued 10 patents this year, and its patent portfolio covers its applications and features of its instruments and products, including microwell-based single-cell capture, preparation, automation, genomic and proteomic analysis, and immunostaining.
“The pace at which these patents are being issued — with 10 granted so far this year and several others under consideration — is remarkable, especially in a field as competitive as single-cell analysis,” says Kalyan Handique, chief technology officer at Celsee and an inventor on its patents. “We are pleased by the claims granted to us in these patents and believe they will bolster our company’s growth in the coming years, particularly through our ability to offer automated solutions for single-cell research.”
The company works to break through traditional barriers of single-cell analysis and deliver clinical-grade technology designed to support the life sciences and precision medicine.